Bendectin and birth defects : the challenges of mass toxic substances litigation /

Mostrar otras versiones (1)

Benedictin was prescribed to more than thirty-five million American women from its introduction in 1956 until 1983, when it was withdrawn from the market. The drug's manufacturer, Merrill Dow Pharmaceuticals, a major U.S. pharmaceutical firm, joined a list of other companies whose product liabi...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autor principal: Green, Michael D., 1950-
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Philadelphia : University of Pennsylvania Press, ©1996.
Temas:
Products liability > Drugs > United States.
Toxic torts > United States.
Complex litigation > United States.
Bendectin (Trademark) > Toxicology.
Abnormalities, Human.
Abnormalities, Drug-Induced > legislation & jurisprudence
Consumer Product Safety > legislation & jurisprudence
Doxylamine > adverse effects
Doxylamine > legislation & jurisprudence
Pyridoxine > adverse effects
Pyridoxine > legislation & jurisprudence
Responsabilité du fait des produits > Médicaments > États-Unis.
Responsabilité pour dommages causés par les substances dangereuses > États-Unis.
Instances complexes > États-Unis.
LAW > Administrative Law & Regulatory Practice.
LAW > Civil Procedure.
LAW > Legal Services.
POLITICAL SCIENCE > Government > Judicial Branch.
Abnormalities, Human
Bendectin (Trademark) > Toxicology
Complex litigation
Products liability > Drugs
Toxic torts
United States
Acceso en línea:Texto completo
Tabla de Contenidos:
  • Frontmatter
  • Contents
  • Preface
  • Acknowledgments
  • Chapter 1. A Birth Defect Child Is Born
  • Chapter 2. Locating Bendectin Within the Mass Toxic Landscape
  • Chapter 3. The Science of Determining Toxic Causation
  • Chapter 4. The Food and Drug Administration
  • Chapter 5. The Wm. S. Merrell Company
  • Chapter 6. A Mother's Quest
  • Chapter 7. The Mekdeci Case
  • Chapter 8. The Unraveling Of Mekdeci
  • Chapter 9. The Proliferation of Bendectin Litigation
  • Chapter 10. Litigating a Multidistrict Case
  • Chapter 11. The Withdrawal of Bendectin
  • Chapter 12. Forging a Mass Toxic Substances Trial
  • Chapter 13. The Settlement and Unsettlement of MDL-486
  • Chapter 14. The MDL-486 Trial
  • Chapter 15. Aggregative Procedure in Mass Toxic Substances Litigation
  • Chapter 16. The Third Phase of Bendectin Litigation: Oxendine, Richardson, and the Individual Trials
  • Chapter 17. The Legacy of Bendectin for Toxic Causation Law
  • Chapter 18. The Lessons and Non-Lessons of Bendectin Litigation
  • Selected Bibliography
  • Index

Ejemplares similares